In this week’s Longevity News Roundup, Phil Newman and Nina Patrick explore new research shaping the future of longevity science, from neuroprotective obesity drugs and fasting-mimicking supplements to bionic vision implants and AI-driven athletic longevity platforms.

• A growing body of research suggests that GLP-1 receptor agonists may influence brain aging. A recent review in the Journal of Clinical Investigation highlights how these drugs could support neuronal energy production, stimulate autophagy, reduce chronic inflammation, and improve synaptic resilience. Early human studies show signals of preserved brain metabolism in Alzheimer’s patients, though larger clinical trials are still underway.
• New diagnostic tools for neurodegeneration are also emerging. Startup Amydis received funding from the National Institute on Aging to develop an eye-based molecular imaging test for Amyotrophic Lateral Sclerosis (ALS). Their approach uses fluorescent tracers that bind to TDP-43, allowing early disease signatures to be detected through routine retinal imaging.
• In metabolic health, Mimio Health reported results from a randomized controlled trial testing a fasting-mimetic supplement. The formulation includes Spermidine and Nicotinamide, compounds that rise during prolonged fasting. Over eight weeks, participants showed improvements in fasting glucose and lipid markers, suggesting the possibility of replicating certain fasting signals without caloric restriction.
• Hardware innovation is also advancing longevity care. Science Corporation raised $230 million to scale its PRIMA retinal implant, a tiny photovoltaic chip placed beneath the retina. Working with specialized glasses that project infrared patterns, the implant converts light signals into electrical stimulation, restoring basic visual perception for patients with advanced geographic atrophy.
• In sports longevity, Capriroso launched a new training intelligence system designed for endurance athletes. By combining sleep metrics, heart rate variability, training load, and recovery data, the platform aims to optimize performance across decades rather than short-term race cycles.
• Finally, emerging research into sleep and circadian biology continues to reshape dementia prevention strategies. Studies show that disrupting circadian rhythms can trigger inflammatory changes in brain immune cells known as microglia, which may contribute to neurodegenerative disease. Researchers are also studying hibernating animals to understand how certain species tolerate extreme metabolic stress and reverse neurological damage, offering potential new targets for human therapies.

_____________________

News & References:

• GLP-1 drugs hint at protection against neurodegeneration → https://longevity.technology/news/glp-1-drugs-hint-at-protection-against-neurodegeneration/
• Amydis lands NIA funding to detect ALS in the eye → https://longevity.technology/news/amydis-lands-nia-funding-to-detect-als-in-the-eye/
• Fasting mimetic shows metabolic effects in trial → https://longevity.technology/news/fasting-mimetic-shows-metabolic-effects-in-trial/
• Science Corp lands $230m to commercialize vision restoration chip → https://longevity.technology/news/science-corp-lands-230m-to-commercialize-vision-restoration-chip/
• Capriroso launches platform for athlete longevity → https://longevity.technology/news/capriroso-launches-platform-for-athlete-longevity/
• Sleep rhythms and dementia risk link emerges → https://longevity.technology/news/sleep-rhythms-and-dementia-risk-link-emerges/

_____________________

Hosts:

Phil Newman: ⁠⁠⁠⁠https://qrco.de/bgXpNY⁠⁠⁠⁠

Nina Patrick: ⁠⁠⁠⁠https://qrco.de/bgXpKn⁠